CD274 and neoplasm: Monoclonal antibodies targeting PD-1 or PD-L1, such as nivolumab, atezolizumab, or durvalumab, effectively prevent the inhibitory signaling and reactivate T-cell-mediated cytotoxicity against tumor cells.